Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 12, 2013
Colder Products Company - Quick and easy sterile connections for single-use biopharmaceutical processing
Advertisement
See us at INTERPHEX 2013- Booth #3326 and at BPI-Europe, Booth #15.
AseptiQuik® connectors from Colder Products Company provide reliable, sterile connections without the need for clamps, fixtures or tube welding. Available in a full range from 1/8” (3.2mm) to 1” (26.4mm) flow. Ideal for a wide range of applications, including single-use bag and tubing assemblies, cell banking systems, bioreactors, mixers, sampling and filling. Robust, easy-to-use designs enable users to quickly transfer valuable media with less risk of operator error. For applications where reliability and sterility are a must, Connect with Colder. See the videos at
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement